Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this non-interventional study is to investigate how Seroquel XR and Seroquel IR are used in the clinical practice of inpatients with schizophrenia. This will be done by a retrospective review of medical records to evaluate patients treated with Seroquel XR or Seroquel IR as primary antipsychotic treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Patients with a diagnosis of schizophrenia who have been hospitalized and received at least one dose of Seroquel XR or Seroquel IR during the study period (1st of July 2009 - 30th of September 2010). |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To investigate how Seroquel XR and Seroquel IR are used in the clinical practice of inpatients with schizophrenia | every day for the time period of 15 Oct to 31 Dec 2010 |
| Measure | Description | Time Frame |
|---|---|---|
| To investigate comorbidities of patients with schizophrenia receiving Seroquel XR and IR | every day for the time period of 15 Oct to 31 Dec 2010 | |
| To investigate whether Seroquel XR and Seroquel IR are used to treat different types of inpatients with schizophrenia by evaluation of patient characteristics |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Approximately 300 patients with schizophrenia who have been hospitalized during the study period (1st of July 2009 - 30th of September 2010).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dr Eva Dencker Vansvik, MD | AstraZeneca | Study Director |
| Dr Lars Eriksson, MD | Rättspsykiatriska Vårdkedjan, Hisings-Backa, Sweden | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Falköping | Sweden | ||||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23983980 | Derived | Eriksson L, Hallerback T, Jorgensen L, Carlborg A. Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study. Ther Adv Psychopharmacol. 2012 Dec;2(6):217-26. doi: 10.1177/2045125312453935. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| every day for the time period of 15 Oct to 31 Dec 2010 |
| To investigate the treatment sequence of Seroquel XR and Seroquel IR in the clinical practice of patients with schizophrenia by evaluation of duration, dosage, reason for treatment, and, if applicable, reason for change, with Seroquel XR and Seroquel IR | every day for the time period of 15 Oct to 31 Dec 2010 |
| Gothenburg |
| Sweden |
| Research Site | Helsingborg | Sweden |
| Research Site | Karlskrona | Sweden |
| Research Site | Karlstad | Sweden |
| Research Site | Lund | Sweden |
| Research Site | Malmö | Sweden |
| Research Site | Mölndal | Sweden |
| Research Site | Öjebyn | Sweden |
| Research Site | Stockholm | Sweden |
| Research Site | Trollhättan | Sweden |
| Research Site | Umeå | Sweden |
| Research Site | Uppsala | Sweden |
| Research Site | Vaxjo | Sweden |
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| D001523 | Mental Disorders |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
Not provided
Not provided